Hikma Pharmaceuticals PLC is a publicly traded multinational pharmaceutical manufacturer that specializes in producing generic, specialty, and branded medicines for global markets. The company's core ... Hikma Pharmaceuticals PLC is a publicly traded multinational pharmaceutical manufacturer that specializes in producing generic, specialty, and branded medicines for global markets. The company's core business encompasses the development, manufacturing, and distribution of a diverse portfolio of pharmaceutical products, with an emphasis on non-branded generics and in-licensed medicines. Hikma operates across three primary segments: injectables, generics, and branded pharmaceuticals, with a significant portion of its revenue driven by the supply of generic injectables to hospitals, particularly in North America, which is its largest market. Additional operations span the Middle East and North Africa, the United Kingdom, and various European regions. Founded in 1978, Hikma has established a robust international presence, owning manufacturing plants and R&D centers in several countries. The firm’s strategic focus on expanding access to affordable medicines underscores its commitment to public health and its influential role as a leading supplier in key regions such as MENA and the US. Hikma’s position as a FTSE 100 constituent illustrates its relevance and stability within the global healthcare industry.
Pending data availability
EU Taxonomy Data missing for Hikma Pharmaceuticals
We haven’t collected EU Taxonomy data for Hikma Pharmaceuticals yet, or the company
hasn’t made it publicly available.